Cargando…
Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study
BACKGROUND: Infliximab (IFX) has proven to be an effective addition to the therapeutic arsenal for refractory, fistulizing, and steroid dependent Crohn's disease (CD), with efficacy in the induction and maintenance of clinical remission of CD. Our objective in this study is to report the nation...
Autores principales: | Miheller, Pál, Lakatos, Péter L, Horváth, Gábor, Molnár, Tamás, Szamosi, Tamás, Czeglédi, Zsófia, Salamon, Ágnes, Czimmer, József, Rumi, György, Palatka, Károly, Papp, Mária, Jakab, Zsolt, Szabó, Andrea, Gelley, András, Lakatos, László, Barta, Zsolt, Balázs, Csaba, Rácz, István, Zeher, Margit, Döbrönte, Zoltán, Altorjay, István, Hunyady, Béla, Simon, László, Papp, János, Banai, János, Nagy, Ferenc, Lonovics, János, Újszászy, László, Műzes, Györgyi, Herszényi, László, Tulassay, Zsolt |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755473/ https://www.ncbi.nlm.nih.gov/pubmed/19740450 http://dx.doi.org/10.1186/1471-230X-9-66 |
Ejemplares similares
-
The Behavior of Matrix Metalloproteinases and Their Inhibitors in Colorectal Cancer
por: Herszényi, László, et al.
Publicado: (2012) -
Low bone mass in microscopic colitis
por: Lőrinczy, Katalin, et al.
Publicado: (2011) -
Patient and general population values for luminal and perianal fistulising Crohn’s disease health states
por: Rencz, Fanni, et al.
Publicado: (2019) -
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer
por: Herszényi, László, et al.
Publicado: (2008) -
Gene Expression Changes in Femoral Head Necrosis of Human Bone Tissue
por: Balla, Bernadett, et al.
Publicado: (2011)